FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156450151> ?p ?o ?g. }

• W2156450151 abstract "Abstract Background Cumulative evidence from epidemiological, preclinical and clinical studies suggests estrogens may have psychoprotective effects in schizophrenic patients. Selective Estrogen Receptor Modulators could have therapeutic benefits in schizophrenia for both sexes without being hazardous to gynecological tissues or having feminizing effects. Few studies have been conducted regarding the effects of raloxifene on postmenopausal women suffering from schizophrenia. We conducted this placebo-controlled trial to compare the add-on effect of raloxifene to risperidone versus risperidone with placebo. Methods This was an 8-week, parallel-group, placebo-controlled trial undertaken at two universities affiliated psychiatric Hospitals in Iran. Forty-six postmenopausal women with the definite diagnosis of schizophrenia were enrolled in the study. Patients received risperidone (6 mg/day in 3 divided doses) combined with either placebo (N = 23) or 120 mg/day of raloxifene (N = 23) for 8 weeks. Patients were assessed by a psychiatrist at baseline and at 2 and 8 weeks after the start of medical therapy. Efficacy was defined as the change from baseline to endpoint in score on Positive and Negative Syndrome Scale (PANSS). Results For PANSS scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 1.77, p = 0.18]. For positive subscale scores, there was marginal significant interaction between intervention type and time [F (2, 47) = 2.93, p = 0.06] and there was substantial main effect for time [F (2, 47) = 24.39, p = 0.001] within both groups showing reduction in positive subscale scores across the three time periods. In addition, the main effect comparing two types of intervention was significant [F (1, 48) = 3.78, p = 0.02]. On the other hand, for negative subscale scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 1.43, p = 0.23]. For general subscale scores, the main effect comparing two types of intervention was not significant [F (1, 48) = 0.03, p = 0.86]. Conclusions According to our findings, raloxifene as an adjunctive treatment to risperidone was only superior in improvement of positive symptoms and it was not effective in treating negative and general psychopathology symptoms. Trial registration The trial was registered at the Iranian registry of clinical trials: IRCT201205131556N42" @default.
• W2156450151 created "2016-06-24" @default.
• W2156450151 creator A5021499828 @default.
• W2156450151 creator A5038558607 @default.
• W2156450151 creator A5042620953 @default.
• W2156450151 creator A5051576513 @default.
• W2156450151 creator A5052958799 @default.
• W2156450151 creator A5074774874 @default.
• W2156450151 creator A5088810181 @default.
• W2156450151 creator A5089991986 @default.
• W2156450151 date "2014-07-10" @default.
• W2156450151 modified "2023-10-13" @default.
• W2156450151 title "Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial" @default.
• W2156450151 cites W1489450676 @default.
• W2156450151 cites W1963580478 @default.
• W2156450151 cites W1967614061 @default.
• W2156450151 cites W1980500337 @default.
• W2156450151 cites W2005016581 @default.
• W2156450151 cites W2020522742 @default.
• W2156450151 cites W2035477056 @default.
• W2156450151 cites W2043709248 @default.
• W2156450151 cites W2047419237 @default.
• W2156450151 cites W2048471009 @default.
• W2156450151 cites W2050576459 @default.
• W2156450151 cites W2055400514 @default.
• W2156450151 cites W2063165012 @default.
• W2156450151 cites W2067177349 @default.
• W2156450151 cites W2070688969 @default.
• W2156450151 cites W2073401942 @default.
• W2156450151 cites W2102329283 @default.
• W2156450151 cites W2102722830 @default.
• W2156450151 cites W2103303614 @default.
• W2156450151 cites W2140606211 @default.
• W2156450151 cites W2147385322 @default.
• W2156450151 cites W2157863535 @default.
• W2156450151 cites W2166824705 @default.
• W2156450151 doi "https://doi.org/10.1186/2008-2231-22-55" @default.
• W2156450151 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4100751" @default.
• W2156450151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25012765" @default.
• W2156450151 hasPublicationYear "2014" @default.
• W2156450151 type Work @default.
• W2156450151 sameAs 2156450151 @default.
• W2156450151 citedByCount "38" @default.
• W2156450151 countsByYear W21564501512015 @default.
• W2156450151 countsByYear W21564501512016 @default.
• W2156450151 countsByYear W21564501512017 @default.
• W2156450151 countsByYear W21564501512018 @default.
• W2156450151 countsByYear W21564501512019 @default.
• W2156450151 countsByYear W21564501512020 @default.
• W2156450151 countsByYear W21564501512021 @default.
• W2156450151 countsByYear W21564501512022 @default.
• W2156450151 countsByYear W21564501512023 @default.
• W2156450151 crossrefType "journal-article" @default.
• W2156450151 hasAuthorship W2156450151A5021499828 @default.
• W2156450151 hasAuthorship W2156450151A5038558607 @default.
• W2156450151 hasAuthorship W2156450151A5042620953 @default.
• W2156450151 hasAuthorship W2156450151A5051576513 @default.
• W2156450151 hasAuthorship W2156450151A5052958799 @default.
• W2156450151 hasAuthorship W2156450151A5074774874 @default.
• W2156450151 hasAuthorship W2156450151A5088810181 @default.
• W2156450151 hasAuthorship W2156450151A5089991986 @default.
• W2156450151 hasBestOaLocation W21564501511 @default.
• W2156450151 hasConcept C118552586 @default.
• W2156450151 hasConcept C121608353 @default.
• W2156450151 hasConcept C126322002 @default.
• W2156450151 hasConcept C142724271 @default.
• W2156450151 hasConcept C168563851 @default.
• W2156450151 hasConcept C204787440 @default.
• W2156450151 hasConcept C27081682 @default.
• W2156450151 hasConcept C2776412080 @default.
• W2156450151 hasConcept C2777164284 @default.
• W2156450151 hasConcept C2779727114 @default.
• W2156450151 hasConcept C2779889926 @default.
• W2156450151 hasConcept C2780057945 @default.
• W2156450151 hasConcept C2780135775 @default.
• W2156450151 hasConcept C530470458 @default.
• W2156450151 hasConcept C535046627 @default.
• W2156450151 hasConcept C71924100 @default.
• W2156450151 hasConcept C84606932 @default.
• W2156450151 hasConceptScore W2156450151C118552586 @default.
• W2156450151 hasConceptScore W2156450151C121608353 @default.
• W2156450151 hasConceptScore W2156450151C126322002 @default.
• W2156450151 hasConceptScore W2156450151C142724271 @default.
• W2156450151 hasConceptScore W2156450151C168563851 @default.
• W2156450151 hasConceptScore W2156450151C204787440 @default.
• W2156450151 hasConceptScore W2156450151C27081682 @default.
• W2156450151 hasConceptScore W2156450151C2776412080 @default.
• W2156450151 hasConceptScore W2156450151C2777164284 @default.
• W2156450151 hasConceptScore W2156450151C2779727114 @default.
• W2156450151 hasConceptScore W2156450151C2779889926 @default.
• W2156450151 hasConceptScore W2156450151C2780057945 @default.
• W2156450151 hasConceptScore W2156450151C2780135775 @default.
• W2156450151 hasConceptScore W2156450151C530470458 @default.
• W2156450151 hasConceptScore W2156450151C535046627 @default.
• W2156450151 hasConceptScore W2156450151C71924100 @default.
• W2156450151 hasConceptScore W2156450151C84606932 @default.
• W2156450151 hasIssue "1" @default.
• W2156450151 hasLocation W21564501511 @default.
• W2156450151 hasLocation W21564501512 @default.
• W2156450151 hasLocation W21564501513 @default.

• next